Actively Recruiting
Electroacupuncture Plus Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer
Led by Feixue Song · Updated on 2024-03-21
370
Participants Needed
1
Research Sites
159 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study explores the effectiveness of combining electroacupuncture with olanzapine-containing four-drug antiemetic therapy to mitigate chemotherapy-induced nausea and vomiting (CINV) in patients with breast cancer. The research aims to assess the adjunctive benefits of electroacupuncture in enhancing the antiemetic effects of conventional medication, particularly in the context of highly emetogenic chemotherapy regimens. By investigating the synergistic potential of these modalities, the study seeks to provide insights into optimizing supportive care strategies for patients with breast cancer undergoing intensive chemotherapy treatment.
CONDITIONS
Official Title
Electroacupuncture Plus Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 18 to 75 years, inclusive
- Diagnosed with early-stage breast cancer
- Eastern Cooperative Oncology Group performance status of 0 to 2
- Must be undergoing highly emetogenic chemotherapy
- Adequate organ function
- Premenopausal women must use adequate contraception
You will not qualify if you...
- Scheduled to receive chemotherapy on days 2 to 4 after highly emetogenic chemotherapy
- Received or planned for abdominal radiation therapy within 1 week before Day 1 of cycle 1
- Significant medical or psychological conditions
- Symptomatic primary or metastatic central nervous system malignancy causing nausea or vomiting
- Ongoing vomiting or nausea grade 2 or higher per CTCAE
- Known allergies to study drugs, antiemetics, or dexamethasone
- Fear of electroacupuncture stimulation or allergy to stainless steel needles
- Received acupuncture within 8 weeks prior to highly emetogenic chemotherapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Second Hospital of Lanzhou University
Lanzhou, Gansu, China, 730000
Actively Recruiting
Research Team
F
Feixue Song, Dr
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here